YM BioSciences, Inc. (USA) (AMEX:YMI)

missisagua company. 4 stars on mf.

Small Bio.....rolling the dice

Small biotech cancer play.

Clinical results are also promising in the lower incidence of anemia with the YMI compound. Good results are often anticipated by the market. Here the reward opportunity is far greater than the risk--if only due to the low price of the stock. Being short here has great risk, low reward and requires the same wait for results.

There are currently 4500 YMI shares in my "fund" with break-even of around -0.92 USD.
http://caps.fool.com/Blogs/fund-trades/671856.

Bought in RL at $1.20

zz

There's a move in baby biotech that I call the Sandbag, in honor of the original Indiana Jones movie Raiders of the Lost Ark. In the opening scene, Indiana braves numerous booby traps to reach his goal, the golden head of an Aztec god. Indy knows that removing the head from the pedestal will trigger the collapse of the temple so he has brought a bag of sand with him that approximates the weight of the head. He deftly knocks the head off the pedestal with the bag and leaves the bag in its place. For a moment he thinks he has succeeded in fooling the weight detection system, but then the pedestal starts to sink into the ground and all hell breaks loose.

As you might have guessed, the baby biotech Sandbag occurs when a company bumps a failing lead drug out of their PR statements and replaces it at the top with a new compound. The goal is to cushion or totally avoid the plunging share price that would be precipitated by abandoning the lead program by diverting investors' focus to a new area. If done poorly, the stock may collapse into the pennies like an Aztec temple (see CytRx, Adventrx). On the other hand, companies like Synta and Neurocrine have been much more successful with the move.

After reading YMI's most recent earnings PR, I saw that they've completed the Sandbag maneuver they began about a year ago. The body of the statement features pipeline newcomer CYT387 prominently while former lead compound nimotuzumab has been relegated to the "About YMI" postscript, despite several late stage trials still in progress. Right now, YMI's pedestal seems to be quivering ominously.

I've learned not to count out a biotech because of the messy failure of a lead compound, so I'm keeping an open mind about CYT387. The drug was responsible for elevating the share price over 3.5 after the company reported encouraging response rates in myelofibrosis at ASCO, and the effects compare favorably to Incyte's ruxolitinib which was just approved for the same indication. Updated data from the ongoing phase II trial will be presented at ASH in early December, and strong results could have a very dramatic effect at the current depressed share price. YMI is looking like a potential real buy later this month as long as the world's economic cheese doesn't completely fall off its cracker.

Back down to pre-ASCO run up levels.

Fantastic stock with promising upside potential. The number of institutional holdings has increased dramatically. Promising drugs with upcoming PIII trials opens potential for merger (although unsure if YM wants this). Nick Glover and David Alan have done a fantastic job presenting at various events to increase exposure and ASCO in June. Not too many possible downsides except bad upcoming data results, which seem unlikely thus far. Hoping for the best.

support price will be around $1.72

Such a high rating by CAPS. A bunchof someones knows something good about this situation.

Cancer therapeutic: monoclonal antibody to EGF receptor, less side effects than current drugs, already marketed in 3rd world. Good cash level.

YMI is a small biotech that is moving forward with treatments for various cancers. The ASCO conference may give this stock a big boost if their presentation is positive. Risky but has great upside potential.

Its a chance but I like it, Take the ride!

good fundamentals, high insider buyings the last days.
looks very cheap now.
bought it for real money too

Looks as though YMI's share price is at it's best buying point in quite some time... Will have to see if their remaining products in R&D can progress into phase III's and align this stock again... The phase III trial of tesmilifene showed increased longevity for advanced breast cancer patients, but didn't significantly increase survivability... Unfortunately, people seemed to have overlooked the simple premise that "time is precious." In this case with advanced breast cancer (or similar illness) I would consider an extension of time in a patients life a bittersweet option that many patients, I feel would be inclined to take, under the circumstances.

Even though the drug that was furthest along in development failed, they have two more along the way. Considering the hammering they have taken (assuming the after hours trading report is no lie), I imagine it will rebound substantially sometime in the next couple years. Fair warning - this is a very speculative play.

daviducsb might be on to something...